1. Increasing burden of melanoma in the United States;Linos;J Invest Dermatol,2009
2. BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma;Ribas;J Clin Oncol,2011
3. Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma;Chapman;J Clin Oncol,2011
4. Improved survival with ipilimumab in patients with metastatic melanoma,;Hodi;N Engl J Med,2010
5. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies;Philips;Int Immunol,2015